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As much as 90% of an intravenously (i.v.) injected dose of 
adenovirus serotype 5 (Ad5) is absorbed and destroyed by 
liver Kupffer cells. Viruses that escape these cells can then 
transduce hepatocytes after binding factor X (FX). Given 
that interactions with FX and Kupffer cells are thought to 
occur on the Ad5 hexon protein, we replaced its exposed 
hypervariable regions (HVR) with those from Ad6. When 
tested in vivo in BALB/c mice and in hamsters, the Ad5/6 
chimera mediated >10 times higher transduction in the 
liver. This effect was not due to changes in FX binding. 
Rather, Ad5/6 appeared to escape Kupffer cell uptake 
as evidenced by producing no Kupffer cell death in vivo, 
not requiring predosing in vivo, and being phagocytosed 
less efficiently by macrophages in vitro compared to Ad5. 
When tested as a helper-dependent adenovirus (Ad) vec-
tor, Ad5/6 mediated higher luciferase and factor IX trans-
gene expression than either helper-dependent adenoviral 
5 (HD-Ad5) or HD-Ad6 vectors. These data suggest that 
the Ad5/6 hexon-chimera evades Kupffer cells and may 
have utility for systemic and liver-directed therapies.
Received 12 October 2010; accepted 20 March 2011; published online 
19 April 2011. doi:10.1038/mt.2011.71
IntroductIon
Adenovirus serotype 5 (Ad5) is widely used for liver gene transfer 
studies because of its natural tropism for this organ after systemic 
administration. Recent evidence suggests that this liver tropism is 
dependent on the major capsid protein, hexon, which can bind host 
serum coagulation factors to enhance hepatocyte transduction.1 
More specifically, it was demonstrated that vitamin K dependent 
blood factors VII, IX, X, and protein C enhance transduction of 
Ad5.1–3 Factor X (FX) was found to bind Ad5 hexon with particu-
larly high affinity using its γ-carboxyglutamate domain.4 Cryo-
electron microscopy and hexon mutagenesis techniques localized 
FX binding to the hypervariable (HVR) domains of Ad5 hexon.5,6 
Adenoviral serotypes possess seven HVR domains that differ 
widely in sequence, and in part, define them.7 As such, variations 
in the HVR domain across serotypes and their differences in FX 
binding affinity generally correlate with the ability of adenovirus 
(Ad) serotypes to transduce hepatocytes.4
In addition to viral tropism, HVR domains may have a role in 
sequestration of Ad virions within Kupffer cells. Kupffer cells are 
resident liver macrophages that sequester 90% of the intravenously 
(i.v.) injected Ad5 doses, thus representing a major barrier hepato-
cellular gene transfer.8 Although Kupffer cells comprise only ~7% 
of liver cells,9 they are thought to represent 80–90% of all mac-
rophages in the body10 and therefore represent a significant whole 
body pharmacological “sink” for systemically administered Ad5. 
In addition, Kupffer cells are antigen-presenting macrophages. 
Therefore, rampant uptake of viral antigens into these cells may 
amplify immune responses against the vector.
Uptake by Kupffer cells not only depletes circulating Ad5 
but it kills these cells themselves.11 Kupffer cells can be destroyed 
by “predosing” animals first with a high dose of irrelevant Ad5. 
Four hours later, the therapeutic or reporter-expressing Ad can 
be injected thereby avoiding destruction by the Kupffer cells. 
Predosing is remarkably effective and, in the absence of the 
Kupffer cell sink, virus escapes to other sites as evidenced by its 
ability to increase hepatocyte expression 40-fold and its ability to 
increase killing of distant tumor sites.12
In previous work testing systemic delivery of oncolytic Ads, a 
series of viruses were tested for their ability to mediate this predos-
ing effect.13 Surprisingly, species C Adenovirus serotype 6 (Ad6) 
demonstrated remarkably less efficient predosing as compared to 
the extensively studied species C Ad5. This data suggested that 
Ad5 and Ad6 might have distinctly different interactions with 
liver cells despite their high sequence identity.
Most of the sequence variation between Ad5 and Ad6 is in 
the HVR domains of their hexon proteins.14 Given this, we have 
tested whether this region mediates interactions with liver cells 
by replacing the HVR domains of Ad5 with those from Ad6. 
Comparison of this Ad5/6 vector with Ad5 vector after i.v. injec-
tion, demonstrates remarkable differences in their pharmacology 
and interactions with macrophages and Kupffer cells.
results
Generation of a hexon-chimeric Ad5/6 vector
Given that FX and Kupffer cell interactions are thought occur in the 
HVR domains of hexon, we replaced the HVR region of Ad5 with 
that of Ad6. PCR was used to clone the HVR region of Ad6 with 
terminal ApaI and PstI restriction sites and this was used to replace 
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the corresponding HVR cassette in Ad5. Ad5/6GL expressing the 
eGFP-luciferase (GL) reporter protein was generated by replac-
ing this region of Ad5GL by red recombination (Supplementary 
Figure S1). Replacing the Ad5 HVR domain with that of Ad6 sig-
nificantly decreased the number of charged residues in this region. 
Ad5 contains 31 negatively charged amino acids (blue; aspartic 
acid and glutamic acid) and 17 positively charged amino acids 
(red; arginine, histidine, and lysine). Ad6 displays only 25 nega-
tively and 12 positively charged residues (Supplementary Figure 
S1a). Both vectors retain the glutamic acid 451 (E451) in HVR7 
that is conserved in all FX-binding Ads.6
Ad5/6GL and Ad5GL vectors grew with similar kinetics, 
although Ad5/6GL yielded approximately fivefold fewer virus par-
ticles (vp) and sevenfold fewer plaque forming units after puri-
fication (Supplementary Table S1). Western blotting of Ad5GL 
and Ad5/6GL with serum from Ad5 and Ad5/6-immunized mice 
demonstrated that these antibodies did not crossreact against each 
other’s hexon proteins (data not shown).
Intravenous injection of mice with Ad5/6Gl 
generates higher liver expression when  
compared to Ad5Gl
1 × 1010 vp of Ad5GL or Ad5/6GL was injected into female BALB/c 
mice by three different routes: intramuscular (i.m.), intranasal 
(i.n.), and i.v. by tail vein (Figure 1). Luciferase imaging 24 hours 
later demonstrated that both vectors mediated comparable expres-
sion when injected i.n. By the i.m. route, Ad5GL generated two-
fold higher expression than Ad5/6GL. In stark contrast, Ad5/6GL 
produced >tenfold higher expression in the liver after i.v. injection 
of equal particle numbers. Considering that the Ad5/6 has a lower 
infectious unit titer, this tenfold increase likely underestimates 
Ad5/6 activity. The comparison was repeated four times with sev-
eral different viral preparations with essentially identical results. 
That Ad5/6GL demonstrates lower nasal and muscle transduction 
but higher liver expression indicates a unique biology with respect 
to systemic delivery and liver infection.
FX binds to Ad5/6Gl and is crucial for  
hexon-mediated transduction of Ad5/6Gl in vitro
The binding of Ad5 hexon to vitamin K dependent blood factors, 
particularly FX, has been shown to traffic virions to hepatocytes 
in vivo.2,5 Hexon protein was purified from Ad5GL or Ad5/6GL 
infected cell lysates, immobilized on biosensor chips, and tested 
for binding to human FX using Surface Plasmon Resonance 
(Supplementary Table S2). Consistent with previous work,4 
Ad5 hexon bound FX with high affinity (KD = 1.68 × 10
−9 mol/l). 
In contrast, FX affinity for Ad5/6 hexon was tenfold lower 
(KD = 1.63 × 10
−8 mol/l). Closer inspection revealed that association 
(Ka) of unmodified and chimeric hexon with FX was similar, but the 
latter appeared to dissociate (Kd) more rapidly. These results were 
consistent with the binding kinetics of Ad6 to FX (Supplementary 
Table S2). As previously shown, immobilization of FX on the chip 
instead of hexon increased the KD by approximately tenfold.
4
To assess functional FX binding in vitro, Ad5GL and Ad5/6GL 
were tested for their ability to transduce cells that are nonper-
missive for Ad5 infection. SKOV3 and CHO cell lines have low 
levels of CAR, the coxsackie and adenovirus receptor,13 but in 
the presence of FX, Ad5 is able to transduce these cells.4,6 Both 
viruses were incubated on cells in the presence or absence of 
physiological levels of FX (10 µg/ml) for 3 hours at 37 °C, and 
were assayed for transduction by luciferase activity 24 hours later 
(Figure 2a,c). Transgene expression by both viruses increased 
significantly in the presence of FX. When tested on CHO cells 
expressing CAR, the FX effect was masked (Figure 2b).
Vitamin K dependent blood clotting factors are 
crucial for liver transduction by Ad5/6Gl in vivo
Warfarin inhibits vitamin-K mediated γ-carboxylation of blood 
factors such as FX, decreasing their ability to retarget Ad5 to hepa-
tocytes.12,15 To test if blood factors mediated Ad5/6GL liver trans-
duction in vivo, BALB/c mice were treated with warfarin prior to 
i.v. injection of both viruses (Figure 2d). For both, warfarinization 
dramatically decreased luciferase expression in the liver. The fold 
decrease between mice after warfarinization was twofold for Ad5 
and 18-fold for Ad5/6.
Ad5/6Gl is less efficiently phagocytosed  
by macrophages in vitro
Phagocytic Kupffer cells are a considerable sink for i.v. injected 
Ad5 particles. To test whether the Ad6 HVRs changed recogni-
tion of Ad virions by phagocytic cells, the viruses were incubated 
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Figure 1 In vivo expression of unmodified and chimeric adenoviruses 
when injected via different routes. BALB/c mice were injected with 
1 × 1010 virus particles of either Ad5GL or Ad5/6GL by different routes. 
(a) Mice were imaged 24 hours later using a Lumazone imager: intranasal, 
10-minute 1 × 1 binning, 1,315–1,389 gray values; intramuscular,  10-minute 
2 × 2 binning, 712–1,300 gray values; intravenous, 1 minute 1 × 1 binning, 
1,296–2,000 gray values. Shown are representative white light images 
overlaid with luciferase expression in pseudo-color. (b) Quantification of 
luciferase expression in mice injected via different routes after 24 hours. 
N = 5. *P < 0.05; ns = not significant. Means ± SEM.
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Figure 2 Ad5/6Gl and Ad5Gl interact with blood factors comparably. (a) CHO, (b) CHO cells transiently transfected with coxsackie-adenovirus 
receptor (CAR), or (c) SKOV3 were infected with unmodified or chimeric adenovirus (Ad) vectors (multiplicity of infection 1,000) ± FX (10 µg/ml). 
A luciferase assay was performed after 24 hours to determine transgene expression. N = 6. (d) BALB/c mice were injected subcutaneously with war-
farin (133 µg in 100 µl peanut oil) 3 and 1 day before intravenous injection of 1 × 1010 virus particles (vp) unmodified or chimeric adenoviruses. Mice 
were imaged 24 hours later using a Lumazone imager and quantified for luciferase transgene expression; 3 minutes 2 × 2 binning. N = 5. *P < 0.05; 
**P < 0.005; ns = not significant. Means ± SEM.
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Figure 3 Ad5/6Gl is taken up into macrophages less than unmodified Ad5Gl. (a) adenovirus (Ad) vectors were added to RAW 267.4 cells (mul-
tiplicity of infection 10,000). Cells were harvested 24 hours later and genomic DNA was extracted. Real-time PCR was used to quantify viral and cel-
lular genomes using cytomegalovirus (CMV) and GAPDH specific primers, respectively. Data are normalized to cellular genomes. N = 4. BALB/c mice 
were predosed intravenous (i.v.) with 3 × 1010 virus particles (vp) in 100 µl in phosphate-buffered saline (PBS). After 4 hours, the mice were injected 
with 1 × 1010 vp in PBS of unmodified or chimeric Ad vector. Mice were imaged and luciferase expression was quantified (b) 24 hours after Ad vector 
injection and (c) over time. N = 5. (d) Varying doses of Ad vectors were injected i.v. into mice. After 1 hour, mice were euthanized and 20 ng of tissue 
from the large liver lobe was harvested. Total DNA was extracted and real-time PCR was used to quantify viral genomes using CMV primers. *P < 0.05; 
**P < 0.005; ns = not significant. Means ± SEM.
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with RAW 264.7 murine monocyte-macrophage cells in vitro. 
Although we determined low levels of expression in vitro (data 
not shown) these cells are thought to predominantly phagocytose 
rather than endocytose Ad.16 Given this, phagocytosis was assessed 
by incubating the cells with 10,000 vp/cell of Ad5 or Ad5/6 and 
after 24 hours, viral genomes were quantified by real-time PCR 
(Figure 3a). This analysis revealed that ~50% less Ad5/6GL viral 
genomes were taken up into RAW macrophages when compared 
to unmodified Ad5GL.
Ad5/6Gl evades Kupffer cells for increased  
liver expression in vivo
The in vitro RAW cell data suggested that swapping the Ad5 
HVR for Ad6 HVR reduced phagocytosis by macrophage cells. 
To explore this in vivo, mice were predosed by i.v. injection of 
3 × 1010 vp of Ad5-dsRed to destroy Kupffer cells and prevent 
trapping of subsequent doses of Ad.11 Four hours later, predosed 
or control mice were injected i.v. with either Ad5GL or Ad5/6GL 
and luciferase expression was measured over the following 10 
days (Figure 3b,d). Consistent with previous data, predosing 
with Ad5 increased subsequent transduction by Ad5GL by ten-
fold.12,13 In contrast, predosing did not increase liver expression 
by Ad5/6GL. Liver tissue from mice injected with varying doses 
of Ad vectors was harvested analyzed by real-time PCR for viral 
genomes. Despite dramatic changes in liver expression, numbers 
of viral genomes 1 hour (Figure 3c) and 24 hours (data not shown) 
between the two vectors were similar.
Elimination of Kupffer cells by predosing above suggested that 
Ad5 was being trapped by Kupffer cells while Ad5/6 is not. Since it 
has been previously shown that Ad5 subsequently causes extensive 
Kupffer cell depletion, we hypothesized that Ad5/6 would induce 
less Kupffer cell death. To test this, mice were injected i.v. with 
phosphate-buffered saline (PBS), a low dose (1 × 1010 vp) or a high 
dose (3 × 1010 vp) of either Ad5 or Ad5/6. Six hours later, the large 
liver lobes of the liver were harvested and immunohistochemistry 
for F4/80 was performed to detect Kupffer cells (Figure 4). Six 
hours after injection, the high dose of Ad5 caused a 20-fold reduc-
tion in F4/80+ cells while Ad5/6 caused only a threefold decrease 
(Figure 4b). These data suggested that in the hours after injection, 
Ad5/6 causes less loss of Kupffer cells from the liver than Ad5.
When Kupffer cells are killed by Ad5, they release lactate 
dehydrogenase (LDH) into the blood within 30 minutes of 
virus injection.11 To test this, Ad5 and Ad5/6 were injected at 
increasing doses into mice and LDH levels were measured in 
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Figure 4 Ad5/6 depletes Kupffer cells less than Ad5. BALB/c mice were 
injected intravenous (i.v.) with phosphate-buffered saline, a low dose 
[1 × 1010 virus particles (vp)], or a high dose (3 × 1010 vp) of adenovirus (Ad) 
vectors. Six hours later, the large lobe of the liver was harvested, paraffin 
embedded and sectioned (4 µm thick). (a,c–f) Immunohistochemical stain-
ing of Kupffer cells (anti-F4/80 macrophage marker). (b) Quantification of 
F4/80 positive cells 6 hours after i.v. injection of Ad vectors. **P < 0.005; 
ns = not significant. Means ± SEM.
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Figure 5 Ad5/6 demonstrates reduced toxicity in vivo. (a) BALB/c 
mice were injected intravenous with up to 1 × 1011 virus particles (vp) of 
adenovirus (Ad) vectors. Serum was harvested 30 minutes later and ana-
lyzed for lactate dehydrogenase levels. N = 3. BALB/c mice were injected 
intravenously with 2.5 × 1011 vp of Ad vectors. (b) Serum was harvested 
at 72 hours and assayed for alanine aminotransferase (ALT) levels. N = 3. 
(c) Serum was harvested at 6 hours and assayed for interleukin-6 levels 
(IL-6). N = 3. **P < 0.005; ns = not significant. Means ± SEM.
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serum harvested 30 minutes later (Figure 5a). Under these con-
ditions, LDH levels rose with increasing doses of Ad5GL virus. 
In contrast, even the highest dose of Ad5/6GL did not increase 
LDH levels, indicating that Kupffer cells remained viable at least 
at 30 minutes. The threefold loss of F4/80+ cells observed in 
Figure 4 at 6 hours suggests that Ad5/6 may cause lower toxic-
ity than Ad5 and that this may manifest later than 30 minutes 
after injection.
Ad5/6Gl reduces toxicity
Ad5/6 appears to cause less Kupffer cell death which might impact 
the release of inflammatory mediators by these phagocytic cells 
and reduce liver damage. To test this, high doses of each vector 
(2.5 × 1011 vp) were injected i.v. into BALB/c mice and blood was 
harvested at 72 hours later to measure hepatocyte damage by 
release of alanine aminotransferase (ALT) into the blood. While 
both viruses produced relatively low liver damage (Figure 5b), 
ALT levels were significantly lower by Ad5/6GL than Ad5GL. 
Changes in Kupffer cell uptake and systemic cell transduction 
might also modify the innate immune response to the viruses. 
To test this, blood was also drawn 6 hours after injection of the 
high dose viruses and interleukin-6 (IL-6) levels were assayed 
(Figure 5c). In this case, IL-6 levels were similar suggesting 
that systemic innate immune responses are not overtly different 
between Ad5 and the Ad5/6 chimera.
Ad5/6Gl does not increase liver expression  
in c57Bl/6 mice
C57BL/6 mice are a fortuitous negative control for Kupffer effects 
on Ad. When C57BL/6 mice are injected with equal doses of 
Ad5, gene expression is significantly higher than in BALB/c mice. 
This effect is due in part to 20 times as many Ad genomes being 
sequestered in Kupffer cells in BALB/c mice than in C57BL/6 
mice.17 Given this, we compared Ad5 and Ad5/6 in C57BL/6 mice 
after i.v. injection (Figure 6a). In these mice, the Ad5/6 chimera 
showed no enhanced luciferase activity consistent with reduced 
Kupffer cell uptake in these mice.
Ad5/6Gl increases liver expression in hamsters
Syrian hamsters are thought to be an optimal model for Ad5 biol-
ogy, since these animals support Ad5 infection better than mice.18 
To determine whether Ad5/6 activity was a peculiarity of BALB/c 
mice, 1 × 1010 vp of Ad5 and Ad5/6 were injected intrajugularly 
into Syrian hamsters (Figure 6b,c). Consistent with the BALB/c 
model, Ad5/6GL generated threefold greater luciferase expression 
in the liver compared to Ad5GL. This data suggests that Kupffer 
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cell uptake of Ad5 and improved transduction by Ad5/6 is a com-
mon effect across different species.
Helper-dependent Ad5, Ad6, and Ad5/6 vectors
Helper-dependent adenoviral (HD-Ad) vectors have improved 
safety profiles and extended expression when compared to rep-
lication defective (RD) Ad vectors.19–21 To test whether the hexon 
chimera modified HD-Ad vector biology, an HD-Ad5 vector 
expressing eGFP-luciferase was packaged by Ad5, Ad5/6, and 
Ad6 helper viruses.22 In vitro comparison of transduction of A549 
cells by HD-Ad5, Ad5/6, and Ad6 by luciferase assay confirmed 
that all three helper dependent vectors transduced A549 cells to 
a similar degree, although transduction was fourfold less than 
that the first generation Ad5 and Ad5/6 vectors (data not shown). 
HD-Ads were injected i.v. into BALB/c mice and imaged 24 hours 
later (Figure 7). Consistent with the RD vectors, HD-Ad5/6GL 
expressed 2.5-fold more luciferase in the liver than HD-Ad5. 
Interestingly, HD-Ad5/6 also demonstrated ~1.7-fold greater 
luciferase expression than HD-Ad6.
To test whether the chimera might have utility for liver gene 
therapy for hemophilia, a helper-dependent vector expressing 
human Factor IX (hFIX) transgene from a hepatocyte-specific 
promoter was also packaged with Ad5, Ad5/6, and Ad6 helper 
viruses. When injected into BALB/c mice, HD-Ad5/6-hFIX 
produced approximately threefold and approximately twofold 
higher levels of serum hFIX after 1 week when compared to both 
HD-Ad5 and HD-Ad6, respectively (Figure 8a). This statistical 
trend continues for at least 3 weeks (Figure 8b). These data sug-
gest that the Ad5/6 chimeric virus may have utility for long-acting 
HD-Ad-based liver-directed gene therapy.
dIscussIon
It is widely known that Ad5 rapidly localizes to the liver after sys-
temic administration, thus highlighting its potential use as a liver 
gene therapy vector. Ad5 hexon binds circulating FX with high 
affinity, which then acts as a “molecular bridge” for binding to 
hepatocytes.4,5,23 Another species C adenovirus, Ad6, was reported 
to have a similar affinity for FX,4 but a potentially different inter-
action with Kupffer cells.13 We genetically replaced the Ad5 HVR 
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cassette with that of Ad6 in order to study the role of this region 
in liver transduction.
When injected i.v. into BALB/c mice, Ad5/6 exhibited a tenfold 
increase in liver expression compared to Ad5, but lower expression 
when injected i.m. or i.n. In vitro functional assays confirmed the 
role of vitamin K dependent blood factors in both Ad5 and Ad5/6 
hepatocyte transduction, and in vivo ablation of blood factors with 
warfarin reduced liver transduction for both vectors. This implies 
the necessity of FX binding for liver tropism, although despite the 
injection of warfarin, Ad5/6 expression remained higher than that of 
Ad5. Moreover, surface plasmon resonance (SPR) analysis revealed 
that Ad6 and Ad5/6 had lower affinity of for FX compared to Ad5. 
These results indicate that the interaction of Ad5/6GL with blood 
factors is just sufficient for cell binding and liver tropism, but is 
unlikely to be the underlying cause of increased liver transduction.
Within the liver, Kupffer cells take up the majority of systemi-
cally injected Ad5 via scavenger receptors.8,24 Scavenger receptors 
are thought to recognize charge clusters,25 it is therefore interest-
ing that 20% of the amino acids in Ad5 HVR loops is either nega-
tively charged (D, E) or positively charged (H, K, R). For example, 
HVR1 has a net negative charge of 13. Conversely, Ad6 HVR1 has 
net negative charge of only eight or five fewer than Ad5. When all 
720 hexons are considered in aggregate, we hypothesized that this 
40% decrease in charge could significantly decrease recognition of 
Ad5/6 by Kupffer cells.
Consistent with this, Ad5/6 was phagocytosed 50% less effi-
ciently than Ad5 by macrophages in vitro. In vivo, we show by three 
assays that Ad5/6 interacts with Kupffer cells to a lower degree 
than Ad5. First, eliminating Kupffer cells by predosing before Ad 
vector injection conferred no increase in liver transduction for 
Ad5/6, while Ad5 received a marked boost. Second, we show by 
immunohistochemistry that a high dose of Ad5 depletes Kupffer 
cells dramatically by 20-fold, while Ad5/6 decreases Kupffer cells 
by only threefold. Finally, we show Ad5 killed Kupffer cells in a 
dose-dependent fashion as measured by LDH release. On the 
other hand, Ad5/6 generated constant levels of LDH even at high 
doses, although increased variability in LDH measurements at 
higher doses may indicate some Kupffer cell killing. These data 
indicate that the Ad6 HVRs appear to interact to a significantly 
lesser degree with Kupffer cells in vivo.
Ad5 and Ad5/6 were compared in RD vectors, but the effect 
of RD-Ad6 was not measured due to the lack of a RD Ad6 vector 
containing the luciferase transgene. Instead, the Ad5, 6, and 5/6 
were compared in HD-Ad vectors. A luciferase assay showed that 
HD-Ad vectors showed at least twofold decreased transduction 
in vitro (data not shown). Nevertheless, HD-Ad5/6 demonstrated 
significantly increased liver expression compared to Ad5, although 
the fold increase was not as large. It was interesting to observe 
that Ad5/6 was also better at transducing liver than Ad6. This may 
have resulted from the longer fiber shaft of the Ad5 fiber, which is 
generally more efficient compared to the shorter fiber of Ad6.14,26 
Fiber shaft length may also explain why HD-Ad6 exhibited such 
poor expression in muscle compared to HD-Ad5 or HD-Ad5/6.
Ad5/6 showed markedly increased expression in BALB/c 
mice and Syrian hamsters. Interestingly, Ad5/6 had no benefit 
in C57BL/6 mice. Recently, Vigant et al. also found differences 
in behavior between hexon-modified Ad5 vectors in these two 
mice strains.27 Snoeys et al. determined that the overall number 
of Kupffer cells between the two mouse strains is not signifi-
cantly different, but consistent with our data, BALB/c mice take 
up approximately sixfold more Ad DNA in their nonparenchy-
mal cells than C57BL/6 mice, although both mice take up large 
quantities of virus.17 When analyzed by cell type, they showed 
that BALB/c Kupffer cells took up ~20 times more Ad DNA than 
C57BL/6 cells after an i.v. injection of the vector. Since endothelial 
cells also express scavenger receptors,28,29 fundamental differences 
in the location, types, and/or density of these receptors between 
animals may also explain why Ad5 and Ad5/6 expressed similarly 
in C57BL/6 mice. Variations in scavenging and sequestration of 
vectors beyond Kupffer cells (i.e., in hepatocytes endothelial cells, 
blood cells, etc.) may also explain why the ALT hepatotoxicity lev-
els were twofold greater in Ad5 compared to Ad5/6.
When adenoviruses from species B, C, and D were tested for 
Kupffer uptake and hepatocyte infection, the species B and D 
viruses appeared to evade both cell types.13 While this makes them 
potentially excellent for systemic therapies that need to avoid the 
liver, it also obviates their use for efficient liver-directed gene ther-
apy. Conversely, species C viruses are able to infect hepatocytes, 
but are also absorbed by Kupffer cells to varying degrees. The 
Ad5/6 chimera appears to bridge these two biologies by evading 
Kupffer cells while still being able to efficiently infect liver hepa-
tocytes. Evading Kupffer cells and macrophages is likely generally 
advantageous for improving virus pharmacology for liver and sys-
temic therapy. Since dendritic cells also express scavenger recep-
tors,30,31 evading phagocytosis by any antigen presenting cell may 
reduce adaptive responses against Ad and its transgene products.
MAterIAls And MetHods
Cell culture. Human embryonic kidney cells (293) were purchased from 
Microbix (Toronto, Ontario, Canada). A549 Human Lung Carcinoma 
cells (ATCC CCL-185; ATCC, Manassas, VA) and RAW 264.7 murine 
monocyte-macrophage cells (ATCC CRL-2278) were purchased from the 
American Type Culture Collection (ATCC). All cells were maintained in 
Dulbecco’s modified Eagle’s medium containing 10% heat-inactivated fetal 
calf serum (Gibco, Carlsbad, CA) and penicillin/streptomycin at 100 U/ ml 
(Gibco).
Adenoviruses. Ad5GL and Ad5dsRed: First-generation, replication-defec-
tive (E1 and E3 deleted) Ad5 vectors carrying enhanced green fluorescent 
protein and luciferase fusion gene (GL) or dsRed were produced with the 
AdEasy system (Qbiogene, Irvine, CA/MP Biomedicals, Solon, OH) in 293 
cells as described previously.16
Ad6: Wild type Ad6 (ATCC).
Ad5/6GL: Ad6 viral genomic DNA was purified using a PureLink Viral 
RNA/DNA Mini Kit (Invitrogen, Carlsbad, CA) and the HVR cassette was 
amplified by PCR (F primer 5′-TACTTTGACATCCGCGGCGTGCTGG-3′ 
and R primer 5′-GTGGGGCCATGGGGAAGAAGGTGGCG-3′), cut 
with ApaI and PstI and cloned into the Ad5GL backbone. 293 cells were 
transfected with the full-length recombined construct using Polyfect reagent 
(Qiagen, Valencia, CA). All viruses were purified on two consecutive CsCl 
gradient centrifugations, desalted using Econopac 10-DG chromatography 
columns (Bio-Rad, Hercules, CA), resuspended in 0.5 mol/l sucrose in 
KPBS and stored at −80 °C. Viral particle concentration was determined by 
A260 measurements. Viral plaque forming units and TCID50 was determined 
by serial dilution of virus on 293 cells. Typical yields for Ad5 and Ad5/6 
were 3.4 × 1012 and 6.4 × 1011 vp/ml. Particle/plaque forming units (TCID50) 
ratios were 108 and 404 for Ad5GL and Ad5/6GL, respectively.
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Helper-dependent adenoviral vectors: The chimeric helper virus 
AdNG177 contains the Ad6 HVR region in an otherwise serotype 5 
genome and was constructed by replacing the 6710 bp Sfi I fragment in 
the serotype 5 helper virus AdNG16332 with the 6815 bp Sfi I fragment 
from Ad5/6GL. HDAd5/6-GL was produced by coinfecting 116 cells 
with AdNG177 and HD5-GL22 as described in detail elsewhere.33 
HDAd5/6-hFIX was produced by coinfecting 116 cells with AdNG177 
and HDD21.7E4PEPCK-hFIX-WL34 as described in detail elsewhere.33 
All vector particle numbers were determined by absorbance at 260 nm 
and confirmed by real-time PCR. Transduction of different vectors was 
compared by luciferase assay.
Animals. Female BALB/c, C57BL/6 or male Syrian hamsters were purchased 
from Harlan Sprague-Dawley (Indianapolis, IN). They were housed in the 
Mayo Clinic Animal Facility under the Association for Assessment and 
Accreditation of Laboratory Animal Care (AALAC) guidelines with animal 
use protocols approved by the Mayo Clinic Animal Use and Care Committee. 
All animal experiments were carried out according to the provisions of the 
Animal Welfare Act, PHS Animal Welfare Policy, the principles of the NIH 
Guide for the Care and Use of Laboratory Animals, and the policies and pro-
cedures of Mayo Clinic. Blood was collected from the cheek in BD Microtainer 
tubes and serum was separated by centrifugation for 1 minutes at 16,000g.
Ad injections. All viruses were diluted in PBS but were brought up in dif-
ferent volumes depending on the route of injection. For mice: i.n. (10 µl 
in left nare), i.m. (50 µl total, 25 µl per hind leg muscle), and i.v. (100 µl in 
the tail vein). In hamsters: i.m (200 µl total, 100 µl per hind leg muscle), 
and i.j. (intrajugular; 200 µl in the jugular). For predosing, mice were first 
injected i.v. with 3 × 1010 vp of Ad5dsRed in 100 µl of PBS 4 hours before 
i.v. injection of 1 × 1010 vp of Ad5GL or Ad5/6GL. For toxicity experiments, 
2.5 × 1011 vp was injected i.v. For LDH assay, up to 1 × 1011 vp was injected 
i.v. For FIX experiments, 2.5 × 1010 vp was injected i.v. For all other experi-
ments, mice were injected with a total viral dose of 1 × 1010 vp.
Warfarinization. Mice were injected subcutaneously with 133 µg warfarin 
in 100 µl peanut oil both 3 days and 1 day prior to i.v. injection of Ad.
In vivo bioluminescence imaging. Mice and hamsters were anesthe-
tized with ketamine/xylazine and injected intraperitoneally with 100 µl 
(for mice) or 200 µl (for hamsters) of d-luciferin (20 mg/ml; Molecular 
Imaging Products, Bend, OR). Animals were imaged on the Lumazone 
Imagine System (Photometrics, Roper Scientific, Tucson, AZ) for 1–10 
minutes with 1 × 1 or 2 × 2 binning using no filters or photomultiplication. 
Lumazone imaging software was used to determine total light intensity per 
mouse (photons/second) for data analysis.
SPR analyses. FX protein was purchased from Hematologic Technologies 
(Essex Junction, VT). Ad5GL and Ad5/6GL hexon was purified from 
supernatants of CsCl virus preparations. Hexon protein was further puri-
fied and buffer exchanged on a 10G and then G-75 Sephadex column 
(Bio-Rad) into Hank’s buffered salt solution. Hexon and FX protein was 
immobilized onto research grade CM5 sensor chips using the Biacore 2000 
instrument and the amine coupling reagents (Biacore, Pittsburgh, PA). All 
data was collected in replicates of three for each concentration of analyte.
In vitro luciferase assay. To detect luciferase expression in vitro, CHO, 
CHO-CAR, SKOV3, and RAW 264.7 cells were plated to 80–90% conflu-
ency in 96-well plates and infected with varying multiplicities of infec-
tion of Ad vectors. After a 24 hours incubation at 37 °C, cells were lysed 
with cold passive lysis buffer (Promega, Madison, WI). Luciferase assay 
reagent was added and relative luminescence units was measured with the 
Beckman Coulter DTX 880 Multimode Detector system.
Uptake of virus into RAW 264.7. RAW 264.7 cells were seeded to 85–90% 
confluency in 24 well plates and virus was applied to cells at an multiplic-
ity of infection 10,000 for 24 hours. Media and noncell bound virus was 
removed and cells were harvested. DNA was extracted using the DNeasy 
Blood and Tissue kit according to the manufacturer’s protocol (Qiagen) 
with an RNase A digestion. Real-time PCR was performed as described 
below for both viral [cytomegalovirus (CMV)] and cellular (GAPDH) 
genomic targets. Reactions were performed in triplicate with uninfected 
cellular DNA as the negative control.
In vivo vector genome quantification. Mice were injected with varying 
doses of Ad vectors. After 1 or 24 hours, animals were euthanized and 20 ng 
of the large liver lobe was harvested. DNA was extracted using the DNeasy 
Blood and Tissue kit according to the manufacturer’s protocol (Qiagen) 
with an RNase A digestion. Real-time PCR was performed as described 
below for both viral (CMV) genomic targets. Reactions were performed in 
triplicate with a PBS injected mouse as the negative control.
Quantitative real-time PCR. Concentration of DNA samples was 
determined by Abs260 and then diluted to 20 ng/µl. Real-time PCR 
was performed on the DNA in an Applied Biosystems Prism 7900HT 
sequence detection system with SDS 2.3 software. Each well contained 
10 µl Sybr Green (Applied Biosystems, Warrington, UK), 1 µl H2O, 
2 µl of 3 µmol/l F Primer, 2µl of 3 µmol/l R Primer, and 5 µl sample (i.e., 
100 ng DNA/well). The parameters used were one cycle of 95 °C for 15 
minutes, and 40 cycles of 95 °C for 15 seconds, 55 °C for 1 minute, and 
72 °C for 30 seconds. To normalize data, PCR was done for both the 
cellular housekeeping gene GAPDH (using previously published F 
primer 5′-CGTGTTCCTACCCCCAATGT-3′ and R primer 5′-TGTC 
ATCATACTTGGCAGGTTTCT-3′) and viral CMV gene (F primer 5′-CA 
AGTGTATCATATGCCAAGTACGCCCC-3′ and R primer 5′-CCCCGT 
GAGTCAAACCGCTATCCACGCC-3′).16 Viral DNA was normalized to 
cellular DNA by dividing CMV genomes by GAPDH genomes.
Immunohistochemistry. BALB/c mice were injected i.v. with PBS or Ad 
vectors at a low dose (1 × 1010 vp) or at a high dose (3 × 1010 vp). After 6 
hours, the large liver lobe was harvested and incubated over night at room 
temperature in formalin. Tissue was embedded in paraffin and cut to 4 µm 
sections. These were probed with rat anti-F4/80 primary (MCA497EL; 
AbD Serotec, Raleigh, NC) at a 1:200 dilution and ah horseradish peroxi-
dase-conjugated anti-rat secondary, with DAB substrate. Quantifying posi-
tively stained cells: Images of five fields of view for each mouse section were 
taken. The ImageJ software was used to convert them to binary images, and 
the “Threshold” feature was used to separate out positively stained cells 
from background nuclei. “Analyze particles” was used to count numbers of 
stained regions (25-infinity).
Determination of serum IL-6, ALT, and hFIX levels. Serum was collected 
at 6 hours after injection and IL-6 levels were quantified using an OptEIA 
ELISA kit (BD Biosciences, San Diego, CA) according to the manufacturer’s 
protocol. The amount of IL-6 was determined by measuring absorbance at 
450 nm and compared to a standard curve with known IL-6 concentration. 
Serum was collected at 72 hours and ALT was quantified using the Alanine 
Aminotransferase kit (Biotron Diagnostics, Hemet, CA) according to the 
manufacturer’s protocol. Serum was collected 7 days after injection and 
hFIX levels were analyzed by ELISA (Enzyme Research Laboratories, 
South Bend, IN) according to the manufacturer’s protocol.
LDH assay. Serum was collected from BALB/c mice 30 minutes after i.v. 
injection with varying doses of Ad vector. LDH levels were measured 
within 24 hours using the Liquid Reagent kit (Pointe Scientific, Canton, 
MI) and decreasing all volumes by fivefold due to small serum collections. 
LDH activity was measured by incubation at 37 °C and reading the absorp-
tion at 340 nm with a spectrophotometer.
Data analysis. Graphs and statistical analyses were performed using Prism 
Graphical software. Analysis between two and three groups was deter-
mined by unpaired t-test, and one-way ANOVA (Newman–Keuls post-
test), respectively.
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suPPleMentArY MAterIAl
Figure S1. Design and characterization of adenoviral constructs.
Table S1. Ad5/6GL grows to lower particle and infectious unit titers 
compared to Ad5GL.
Table S2. Ad5/6 hexon has lower affinity for Factor X (FX) compared 
to Ad5 hexon.
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Table S1. Replication defective Ad5/6GL grows to lower particle and infectious unit titers 
compared to Ad5GL. 
 RD-Ad5GL RD-Ad5/6GL HD-Ad5GL HD-Ad5/6GL HD-Ad6GL
Concentration (vp/ml) 3.4x1012 6.4x1011 3.5x1012 6.6x1012 2.2x1012
Particle: PFU 212 1391 nd nd nd 
Particle:TCID
50 108 404 nd nd nd 
RD = replication defective; HD = helper-dependent; GL = GFPLuc; nd = not determined 
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Table S2. Adenovirus (Ad) 5/6 hexon has lower overall binding affinity for Factor X (FX) 
compared to Ad5 hexon. KD = equilibrium rate constant; Ka = association rate constant; Kd = 
dissociation rate constant. 
Hexon KD (M) Ka (1/Ms) Kd (1/s) Method 
Ad5 1.59 x 10-8 9.76 x 103 1.53 x 10-4
FX affixed to chip, Ad 
particles flowed over 
Ad6 2.35 x 10-7 8.20 x 103 1.69 x 10-3
FX affixed to chip, Ad 
particles flowed over 
Ad5 1.68 x 10-9 1.90 x 105 3.04 x 10-4
Ad (purified) hexon 
affixed to chip, FX 
flowed over 
Ad5/6 1.63 x 10-8 1.54 x 105 2.50 x 10-3
Ad (purified) hexon 
affixed to chip, FX 
flowed over 
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